Expert Opinion on Drug Safety
Volume 22, 2023 - Issue 3
Original Research
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study
, 
, , , , , , , , & show all
Leanne J. Kossea Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, The Netherlands;b Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The NetherlandsCorrespondence[email protected]
https://orcid.org/0000-0002-9358-2286View further author information
https://orcid.org/0000-0002-9358-2286View further author information, Jette A. van Linta Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, The Netherlands;b Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlandshttps://orcid.org/0000-0003-2303-6199View further author information
https://orcid.org/0000-0003-2303-6199View further author information, , , Eugène van Puijenbroeka Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, The Netherlands;c Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology & -Economics, University of Groningen, Groningen, The Netherlandshttps://orcid.org/0000-0002-2236-1398View further author information
https://orcid.org/0000-0002-2236-1398View further author information, Harald E. Vonkemand Department of Psychology, Health and Technology, University of Twente, Enschede, The Netherlands;e Department of Rheumatology & Clinical Immunology, Medisch Spectrum Twente, Enschede, The Netherlandshttps://orcid.org/0000-0003-3792-7718View further author information
https://orcid.org/0000-0003-3792-7718View further author information, , Michael T. Nurmohamedg Amsterdam Rheumatology & immunology Center | Reade, Amsterdam, The Netherlandshttps://orcid.org/0000-0002-6274-1934View further author information
https://orcid.org/0000-0002-6274-1934View further author information, & Naomi T. Jessuruna Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, The Netherlands;i Unit of Pharmacotherapy, Epidemiology & -Economics, Faculty of Science and Engineering, University of Groningen, Groningen, The Netherlandshttps://orcid.org/0000-0002-8267-1259View further author information
https://orcid.org/0000-0002-8267-1259View further author information show all